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Abstract
Background: Statins are widely used as a cholesterol lowering medication, reduce cardiovascular mortality and morbidity in
high risk patients; and only rarely cause serious adverse drug reactions (ADRs). UK primary care databases of morbidity and
prescription data, which now cover several million people, have potential for more powerful analytical approaches to study
ADRs including adjusting for confounders and examining temporal effects.
Methods: Case-crossover design in detecting statin associated myopathy ADR in 93, 831 patients, using two independent
primary care databases (1991–2006). We analysed risk by drug class, by disease code and cumulative year, exploring
different cut-off exposure times and confounding by temporality.
Results: Using a 12 and 26 week exposure period, large risk ratios (RR) are associated with all classes of statins and fibrates
for myopathy: RR 10.6 (9.8–11.4) and 19.9 (17.6–22.6) respectively. At 26 weeks, the largest risks are with fluvastatin RR 33.3
(95% CI 16.8–66.0) and ciprofibrate (with previous statin use) RR 40.5 (95% CI 13.4–122.0). AT 12 weeks the differences
between cerivastatin and atorvastatin RR for myopathy were found to be significant, RR 2.05 (95% CI 1.2–3.5), and for
rosuvastatin and fluvastatin RR 3.0 (95% CI 1.6–5.7). After 12 months of statin initiation, the relative risk for myopathy for all
statins and fibrates increased to 25.7 (95% CI 21.8–30.3). Furthermore, this signal was detected within 2 years of first events
being recorded. Our data suggests an annual incidence of statin induced myopathy or myalgia of around 11.4 for 16, 591
patients or 689 per million per year.
Conclusion: There may be differential risks associated with some classes of statin and fibrate. Myopathy related to statin or
fibrate use may persist after a long exposure time (12 months or more). These methods could be applied for early detection
of harmful drug side effects, using similar primary care diagnostic and prescribing data.
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Introduction
Existing approaches to detection of rare but serious adverse
drug reactions (ADRs) have limitations. Such associations are
often too rare to be detected in early clinical trials, and may not
appear until after a drug has been more widely released. Post-
marketing surveillance relies on the vigilance of doctors (sponta-
neous reporting), or on prescription event monitoring of relatively
small numbers of exposed individuals over a limited period,
without appropriate controls. Failure to detect adverse drug
reactions early increases the risks associated with drug develop-
ment, with consequent higher drug costs, lower rates of
innovation, and greater healthcare costs. Consequently, current
systems of detection, verification and quantification of ADRs are
disparate, reliant mainly on reports reaching the medical
literature.[1]
Figures from the National Audit Office show that the primary
care drugs bill in England increased from £4.0 billion in 1996 to
£8.2 billion in 2006, with approximately 10 million statin
prescriptions in 2006.[2] Statins are widely and safely used as a
cholesterol lowering medication and have been shown to
significantly reduce cardiovascular mortality and morbidity in
patients with high risk of cardiovascular disease (CVD);[3], and
cause serious ADRs only in a very small minority of patients.
Adverse drug reactions (ADRs) are estimated to affect around 7%
of patients or hospital admissions at an annual cost of around
£380 million in England.[4] A recent article has reviewed the
safety of statins in clinical practice, including myalgia and
myopathy, from numerous clinical trials. However, risks may be
underestimated as these are rare events which may not become
apparent in smaller trials and it is difficult to assess risk associated
with specific drugs.[5] Further studies have identified significant
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2522risks of myopathy and myositis associated with statins and fibrates
using different study designs, in both a US managed care group[6]
and a UK general practice population.[7]
Use of primary care databases for ADR detection
The computerization of primary care in the UK may help in the
development of new and more rapid methods of detecting adverse
drug reactions in clinical practice. The computerisation of primary
care has led to the creation of primary care databases with
longitudinal medical records and drug prescription data covering
several million people.[8] In principle, it is possible to exploit these
databases for a more direct approach to the detection of
associations between drugs and adverse events, as ascertainment
of adverse events can be almost complete in practices with good
systems for collecting diagnostic data.
Because primary care databases follow individuals before,
during and after exposure to drugs, an alternative approach to
control for confounding can be used, based on comparing the rate
of adverse events while exposed to a drug with the rate of adverse
events in the same individuals while they are unexposed to the
drug (case-crossover design). This approach was first developed to
study the effects of transient, short-term exposures on the risk of
acute events[9] and has been used in studies of adverse effects
associated with vaccines[10] and risk of MI after acute respiratory
infection,[11] and more recently increasingly in pharmacovigi-
lance studies.[12–19] Because each individual is included both as a
case and a control, this design considerably reduces confounding
by co-morbidity.
Examples of primary care databases in the UK include the
General Practice Research Database, The Health Information
Network (THIN), QRESEARCH and MediPlus. The size of these
databases gives them sufficient power to detect even rare adverse
drug reactions. Key objectives for this study were to develop a
methodology for exploiting primary care databases for signal
detection and identify how soon an ADR can be identified using
prescribing and medical data.
Methods
Study design
Case-crossover retrospective study from 1991–2006
Data sources
We used The Health Improvement Network (THIN) and
MediPlus databases for this study. These databases classify drugs
by the ATC (Anatomical Therapeutic Chemical classification)
system or equivalent such as the British National Formulary
coding (BNF), and code morbidity using READ codes. The
databases cover an active population of about 5 million people,
and many patients have a follow-up period of over ten years.
The information collected in THIN and MediPlus included for
each patient in the database: comprises (i) consultations coded with
READ codes; (ii) measurements including laboratory test results,
blood pressure, height and weight; (iii) details of drug prescriptions
and (iv) demographic items. The databases also include diagnoses
coded following hospital discharge and outpatient encounters.
Quality measures were also available which allow selection of
complete records with respect to denominator, prescribing and
demographic data. The accuracy of drug prescription data was
high, as prescriptions were generated by general practitioners
using the VISION software from which the THIN and GPRD
databases are generated. Ethical approval for this study was
obtained from the LSHTM ethics committee, the MediPlus
Independent Scientific and Ethics Advisory Committee, and the
NHS South-East Multi-centre Research Ethics Committee
(MREC) for the THIN scheme.
Statistical methods and power calculations
The statistical analyses investigate how causal relationships can
be inferred from the temporal relationship between drug exposure
and outcome, and the size of the effect. A key advantage of the
case-crossover design is that confounding by co-morbidity is
reduced, as each individual acts as their own control.
Sample size calculations show that adequate power to detect
associations can be achieved with relatively small numbers of
events occurring while individuals are exposed, as the rate ratios
for ADR risk are typically large. If the number of events while
unexposed is large compared with the number a of events while
exposed, the standard error of the log rate ratio is simply !(1/a).
Even if the proportion of time exposed (among all individuals who
experience adverse events) is as high as 5%, this approximation
holds well. The minimum detectable log rate ratio for a Type 1
error rate of 2 a and a Type 2 error rate of b is then (za+zb)!(1/a),
where za and zb are the quantiles of the standard normal
distribution. To allow for multiple testing, we have set a=0.0001
and b=0.1. Then with 20 adverse events while exposed (plus a
much larger number of adverse events while not exposed) we can
detect a rate ratio of 3.6, and with 50 adverse events while exposed
we can detect a rate ratio of 2.4.
With more than 50 million person-years, there are enough
events to examine any class of drug-induced ADR that has a
population incidence of at least 1 per million per year.
For all patients in the study the inclusion was the first ever
myopathy code after registration (see Appendix S1). We excluded
any patients who had never had a statin prescription. Patients were
also excluded if they received steroids within 2 weeks of the
myopathy event, were receiving anti-retroviral therapy and had
been diagnosed with any rheumatic disease. We then examined
start of new statin, change of statin prescriptions, or increase in
statin dose in the 12 weeks (and for other exposure periods) prior
to the myopathy event code. Therefore myopathy events were
classified as ‘‘exposed’’ if they occurred within 12 weeks of new/
change of statin and ‘‘non-exposed’’ if not on statin at time of
myopathy event (or had been taking statin for greater than cut off
for exposure time). Numbers of events and time periods of study
were calculated during i) exposure and ii) non exposure. We
calculated denominator periods for exposed and non exposed
groups by year, myopathy code and drug class. RR were
calculated as the ratio of numbers of events when exposed to the
number of events when unexposed, taking into account the
relevant denominator data of ‘‘exposed’’ and ‘‘unexposed’’ times.
SE and 95% CI were calculated using standard methods, as
described earlier. A window of 6 months (to exclude repeat
consultations with the same READ code relating to the initial
diagnosis) was used to examine possible re-challenges which were
defined as new recorded code for myopathy associated with statin
use in the preceding 12 weeks. Altman and Bland tests for
interaction were applied to determine if the difference in RR was
significant between statin classes and periods of study.[20]
Drug exposure data
A list of the corresponding British National Formulary (BNF)
drug codes was assembled for classes of statin, and each class of
adverse events. Data relevant to testing for association between the
statin class and the adverse event class included episodes of
exposure to statins, tables of exposed and unexposed individuals
with morbidity and demographic data, and tables of all adverse
events in this class. For each statin class, and for each class of
Statin Induced Myopathy
PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2522adverse events, data was carefully checked for inconsistencies; for
instance, errors in the prescription record were identified as
outliers in the distribution of calculated daily dosages. Varying
definitions of exposure (12, 26 and 52 weeks) were defined, for
example, as new statin started within last 12 weeks, change of
statin or dose increased within the last 12 weeks.
Morbidity data
Morbidity data were available in the form of READ codes, with
additional health data including clinical and laboratory measure-
ments also available. READ codes include diagnoses, symptoms,
demographic variables, and other types of information. However,
although the drug prescribing data in these databases was highly
consistent, the diagnostic coding was less consistent and required
programming of additional validation checks. Specifically, the
READ classification does not necessarily correspond to disease
entities, and additional work was necessary to define criteria for
classes of adverse events such as myopathy, myalgia and myositis
which were included in the analyses. Additionally we selected
READ codes for creatinine kinase measurements and included
cases who had elevations at .10 times the upper limit of normal
100 IU/ml in females and 150 IU/ml in males, although not all
patients with myopathy have elevated CK values.[21] Codes
included identifying co-morbidities and potential confounders (for
example cases with codes for rheumatic diseases and steroid use
were excluded).
Data management
The workflow data processing methodology used in the project
was based on the InforSense KDE workflow system.[22] The
software originated from the Grid Computing and Service
Computing developed within the Discovery Net, UK e-Science
Pilot Project[23].
The InforSense KDE infrastructure has been designed and
implementedonthe basisofa scientificworkflow,forcomposition of
data analysis tools and resources. The approach supports grid-based
data analytics that require integration of diverse and distributed
sources and enables remote access to the resulting analysis. It also
supports more traditional workflow functionality that can be used to
route tasks between different users. An overview of the InforSense
architecture and workflow methodology, used in preparing the data
files for analyses are shown in Figure 1.
The methodology developed for this study consists of a data
integration strategy for the THIN relational schema, and reusable
modules for patient selection, event selection, event correlation
and exposure definition. All these have been initially defined upon
flat text files, with a view to allow future direct migration to a high-
performance relational database (e.g. Oracle 10 g). Therefore, the
data processing operations have been designed independently
from the underlying storage.
Advantages of this methodology include flexibility, which allows
parameterisation of the key reusable features of the workflow, such
as size of the exposure window, dealing with repeated prescrip-
tions, and handling incomplete dosage information. The workflow
also provides a basis for further studies on other clinical and
prescription datasets.
Results
The data extracted were based on 77,240 statin users from IMS
MediPlus between 1991–2004 and 16,591 statin users from THIN
data between 1991–2006. THIN data contained 516, 331 episodes
of independent types of drug use (including different dosages of
formulations). Table 1 shows descriptive data of patients with
myopathy overall and those with myopathy taking statin therapy.
Patients with myopathy receiving statins were older with a slight
male excess (53.2%). Table 2 gives a breakdown of statin
prescriptions by year from 1991–2005 using the THIN database.
Figure 1. Example of InforSense workflow methodology to derive summary statistics.
doi:10.1371/journal.pone.0002522.g001
Table 1. Descriptive data on all patients from THIN with
myopathy or myalgia READ code.
All patients with myopathy
N=27689
n( % )
Mean [SD] age at event in years 47.8 [18.9]
Aged over 65 years 5565 (20.1%)
Female 15752 (56.9%)
Smokers 8828 (31.9%)
Mean CK [SD] where recorded n=4318 125 [236]; range 0–7550
Mean BMI baseline [SD] kg/m
2 n=23659 26.2 [6.0]
Patients with myopathy
and recent statin use
n=4258
Mean [SD] age at event in years 64.7 [10.8]
Aged over 65 years 2146 (50.4%)
Female 1993 (46.8%)
Smokers 1331 (31.3%)
Mean CK [SD] where recorded n=2135 127 [142]; range 0–3597
Mean BMI baseline [SD] kg/m
2 n=4057 28.2 [5.8]
doi:10.1371/journal.pone.0002522.t001
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year from 1990–2005 using THIN database.
Tables 4 & 5 using independent data from IMS and THIN,
show that using a case-crossover design has the potential to pick up
ADRs such as myopathy or myalgia with statin use, with increased
rates in exposed individuals. We have included first occurrences of
morbidity only, so that individuals with chronic myalgia or
myositis have less influence on the results. The large numbers with
‘‘myalgia unspecified’’ may include some with myopathy, as this
shows a strong association with statin exposure. The IMS data
showed large rate ratios (RR’s) for all myopathy codes and statin
exposure; for all codes apart from polymyositis the rate ratio was
8.2 (95% CI 4.1–16.3). The THIN data show a similar magnitude
of RRs associated with statin exposure, the combined result for all
myopathy codes and statin exposure (within last 12 weeks) was
10.6 (95% CI 9.8–11.4). The magnitude of the RR with known
elevated CK levels was 8.0 (95% CI 5.8–11.1), although CK
values were available on only 5% unexposed and exposed cases.
Using the READ code analyses (THIN), largest risks were
associated with the term ‘‘muscular rheumatism’’ and ‘‘fibrositis
unspecified’’ RR 22.3 (95% CI 6.8–72.6) and 29.1 (95% CI 15.2–
56.1) respectively (part of composite RR given in Table 5).
Tables 6–8 compares events (all myopathy codes) across classes
of statins and fibrates, based on different exposure times, applying
the same exclusion criteria. At 26 weeks exposure, the greatest
risks for myopathy are with fluvastatin RR 33.3 (95% CI 16.8–
66.0) and ciprofibrate RR (40.5 95% CI 13.4–122.0). The RR for
cerivastatin (which was withdrawn in 2001) was 24.7 (95% CI
11.3–54.1). The differences between cerivastatin and atorvastatin
RR for myopathy were found to be statistically significant at 12
weeks RR 2.05 (95% CI 1.2–3.5), but not at 26 weeks and for
rosuvastatin and fluvastatin at 12 weeks and 26 weeks RR 3.0
(95% CI 1.6–5.7) and RR 3.4 (95% CI 1.2–8.8), respectively. At
12 weeks, further differences in RR were identified for atorvastatin
versus fluvastatin and pravastatin RR 0.39 (95% CI 0.24–0.63)
and 0.53 (95% CI 0.40–0.70); and for simvastatin versus
fluvastatin and pravastatin RR 0.44 (95% CI 0.27–0.72) and
0.61 (95% CI 0.46–0.79). At 26 and 52 weeks exposure, risk of
myopathy/myalgia increases with statin exposure RR 19.9 (95% CI
17.6–22.6) and 25.7 (95% CI 21.8–30.3) respectively, compared
with 12 week exposure. Data was analysed for fibrate class alone
(12 week exposure) with RR as follows: bezafibrate 15.2 (95% CI
6.3–36.7), fenofibrate 12.2 (95% CI 2.7–55.9), ciprofibrate 2.4
(95% CI 0.2–22.6). The overall risk for myalgia/myopathy with all
fibrate class (without statin co-prescriptions) was 12.8 (95% CI
6.3–25.9).
Table 2. Statin prescriptions by year using THIN database
1990–2005.
Year
Statin & Fibrate
prescriptions
Statin
prescriptions
Fibrate
prescriptions
1990 1009 203 806
1991 2190 865 1325
1992 2915 1368 1547
1993 3910 1951 1959
1994 4881 2556 2325
1995 6826 3976 2850
1996 10611 7201 3410
1997 15053 11650 3403
1998 20875 17806 3069
1999 28720 25746 2974
2000 39039 35980 3059
2001 50923 47746 3177
2002 65254 61861 3393
2003 81461 77806 3655
2004 97925 94223 3702
2005 87352 84109 3243
doi:10.1371/journal.pone.0002522.t002
Table 3. Statin & fibrate prescriptions by drug class and year using THIN database 1990–2005*.
Year atorvastatin cerivastatin fluvastatin pravastatin rosuvastatin simvastatin bezafibrate fenofibrate ciprofibrate
1990 2 201 742 8
1991 183 682 1249 31
1992 318 1050 1451 71
1993 482 1469 1745 103 89
1994 51 637 1868 1856 192 264
1995 290 670 3016 2111 275 445
1996 453 1183 5565 2463 337 593
1997 783 157 964 1792 7954 2438 356 596
1998 3187 1024 974 2423 10198 2156 346 553
1999 6236 2273 1179 3439 12619 2037 416 512
2000 10750 3583 1296 4813 15538 2041 520 493
2001 16386 3162 2210 6287 19701 2025 674 478
2002 23743 2936 8696 26486 2112 856 425
2003 31092 2668 10061 1171 32814 2223 975 457
2004 37324 1985 9529 4361 41024 2056 1233 413
2005 33460 1268 6658 4227 38496 1670 1237 336
*data for clofibrate omitted.
doi:10.1371/journal.pone.0002522.t003
Statin Induced Myopathy
PLoS ONE | www.plosone.org 4 June 2008 | Volume 3 | Issue 6 | e2522Using a 26 week exposure cut-off, the number of exposed events
4002 in 350 years in 16, 591 patients suggests an annual incidence
of around 11.4 for 16, 591 patients or 689 per million per year,
using THIN data.
Temporal trends and re-challenge
To assess if there was any confounding by temporality; data were
analysed in 3 time periods. Using a 26 week exposure period the RR
showedpossible evidence ofaseculardecreaseacrosseach ofthetime
periods: 1995–8;1999–2002 and 2003–5; 28.7 (95% CI 15.4–53.4);
21.2 (95% CI 16.8–26.9) and 18.8 (95% CI 16.1–21.9) respectively.
This pattern was similar using other exposure cut offs for 12 and 52
weeks. The difference in RR from 1995–98 compared with 2003–5
(26 week data) was found to be statistically significant RR 1.53 (95%
CI 1.2–2.9), and was similar for different periods of exposure, RR
1.79 (95% CI 1.2–2.8), for 12 week exposure. Re-challenge data
revealed 2 statin associated myopathy events following a drug re-
challenge after 6 months or more from the primary episode, with no
intervening coding listed for myopathy events.
Figure 2 shows temporal trend of statin associated myopathy
from 1996–2006 based on cumulative numbers of exposed and
unexposed events (all classes of statin and fibrate). From 1996 it
was apparent that the RR for myopathy/myalgia was significantly
elevated RR 32.2 (95% CI 11.7–88.6), and the precision increased
with time. Figure 3 represents a frequency histogram showing for
patients with myopathy following statin: time distribution back to
most recent increase or start of new statin. The data shown
suggests that most of the cases occur within the first 12 weeks of
statin exposure, although a 26 week exposure cut-off will allow less
misclassification of exposed and unexposed cases.
Discussion
This analysis used a case-crossover design to compare risks
associated with each class of statin and fibrate. We were able to
Table 4. Case-crossover comparison of myopathy/myalgia based on 77240 statin users extracted from the IMS MediPlus database
(1991–2004) using 12 week cut-off for exposure.
Code Text Exposed Events Un-exposed Events Rate Ratio (95% CI)
598 p-yrs 11,206 p-yrs
Myopathy-all codes
Toxic myopathy; proximal myopathy; myopathy unspecified;
Myopathy or muscular dystrophy unspecified
9 19 8.9 (3.5–22.4)
Fibromyalgia 28 59 8.9 (4.2–18.9)
Myalgia/myositis –all specified codes 10 19 2.3 (4.1–23.7)
Myalgia/myositis unspecified 156 409 7.2 (3.4–15.1)
Myalgia unspecified 107 205 9.8 (5.1–18.8)
Myositis unspecified 4 9 8.3 (2.5–27.5)
Total myalgia/myositis/myopathy 314 720 8.2 (4.1–16.4)
Acute renal failure due to rhabdomyolysis 0 2 -
All except polymyositis 314 722 8.2 (4.1–16.3)
The code specific RR are calculated based on denominators which reflect exposed and unexposed time for relevant code text; the total RR is calculated using total
exposed and non exposed times (all codes).
doi:10.1371/journal.pone.0002522.t004
Table 5. Case-crossover comparison of myopathy/myalgia based on 16,591 users extracted from the THIN database (1991–2006)
using 12 week cut off for exposure.
Code Text Exposed Events Un-exposed Events Rate Ratio (95% CI)
204 p-yrs 592 p-yrs
Muscle ligament or fascia disorder 9 2 10.8 (2.3–49.8)
Intercostal myalgia Fibromyalgia 145 74 14.2 (10.7–18.8)
Rheumatism and/or fibrositis unspecified; muscular
rheumatism; rheumatic pain
148 45 18.4 (13.2–25.8)
`Myalgia unspecified 1632 427 9.8 (8.9–11.0)
Myositis unspecified 44 9 9.6 (4.7–19.7)
Myalgia/myositis unspecified 1 2 2.4(0.2–26.2)
Muscle pain 1188 314 9.8 (8.7–11.1)
CK level .1500 IU/L M and .1000 IU F 173 45 8.0 (5.8–11.1)
All myalgia/myositis 3340 918 10.6 (9.8–11.4)
The code specific RR are calculated based on denominators which reflect exposed and unexposed time for relevant code text; the total RR is calculated using total
exposed and non exposed times (all codes).
doi:10.1371/journal.pone.0002522.t005
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analyses which indicated signals had the potential to be picked up
early. Both datasets have independently shown that case-crossover
designs are able to identify associations of myopathy related codes.
Using 12 week exposures: for IMS data, the rate ratio was 8.2
(95% CI 4.1–16.3) for all myopathy codes and statin exposure. For
THIN data, the combined result for all myopathy codes and statin
exposure was 10.6 (95% CI 9.8–11.4). Both RRs were of
comparable magnitude. Statins are increasingly prescribed which
may lead to greater number of events in more recent years,
following DOH and NICE recommendations.[24,25] Further-
more event rates were based on large numbers of exposed
compared with unexposed rates which resulted in RR with more
precise CI (particularly for classes of drug such as atorvastatin).
The magnitude of the RR with known elevated CK levels for
the THIN data for 12 and 26 week cut off for exposure are 8.0
(95% CI 5.8–11.1) and 14.5 (95% CI 7.7–23.7) respectively are
lower than for codes for myopathy alone (for all exposure cut-off
times) suggesting that not all cases of myopathy had elevated CK
levels recorded by their general practitioner, or that not all cases of
myopathy have definitively elevated CK levels. Until recently
laboratory results had to be manually entered onto the electronic
record which is likely to result in the relatively low number of CK
values being captured.
Statins have significant health benefits in patients with high risk
for cardiovascular disease reducing cardiovascular mortality and
morbidity,[3], and serious side effects are rare. When prescribing
statins, any drug risk and benefit must be taken into account. For
Table 6. Case-crossover comparison of myopathy/myalgia based on 16,591 users extracted from the THIN database (1991–2006):
Event rates using 12 week cut off for exposure.
Class of Drug Exposed Events Un-exposed Events Rate Ratio 12 weeks Standard error of RR
204 p-years 592 p-yrs
Atorvastatin 1170 314 8.3 (7.4–9.4) 0.06
Cerivastatin 45 21 17.0 (10.1–28.5) 0.26
Fluvastatin 79 22 21.5 (13.4–34.4) 0.24
Pravastatin 313 78 15.7 (12.3–20.1) 0.13
Rosuvastatin 108 29 7.1 (4.7–10.7) 0.21
Simvastatin 1519 404 9.5 (8.5–10.6) 0.06
All statins 3234 868 10.0 (9.3–10.8) 0.04
Ever use of statin with the following fibrate
Bezafibrate 62 34 18.4 (12.1–27.9) 0.21
Fenofibrate all 32 9 6.2 (3.0–13.0) 0.38
Ciprofibrate 12 7 32.0 (12.6–81.3) 0.48
All fibrates 106 50 18.7 (13.3–26.1) 0.17
ALL statins & fibrates (95% CI) 3340 918 10.6 (9.8–11.4) 0.04
doi:10.1371/journal.pone.0002522.t006
Table 7. Case-crossover comparison of myopathy/myalgia based on 16,591 users extracted from the THIN database (1991–2006):
Event rates using 26 week cut off for exposure.
Class of Drug Exposed Events Un-exposed Events Rate Ratio 26 weeks Standard error of RR
350 p-years 446 p-yrs
Atorvastatin 1401 83 15.2 (12.2–19.0) 0.11
Cerivastatin 59 7 24.7 (11.3–54.1) 0.40
Fluvastatin 92 9 33.3 (16.8–66.0) 0.35
Pravastatin 361 30 25.8 (17.8–37.4) 0.19
Rosuvastatin 128 9 9.9 (5.0–19.4) 0.34
Simvastatin 1825 98 19.5 (15.9–23.9) 0.10
All statins 3866 236 19.1(16.7–21.8) 0.07
Ever use of statin with the following fibrate
Bezafibrate 82 14 25.4 (14.4–44.8) 0.29
Fenofibrate all 39 2 9.0 (2.2–37.1) 0.73
Ciprofibrate 15 4 40.5 (13.4–122.0) 0.56
All fibrates 136 20 27.1 (17.0–43.4) 0.24
ALL statins & fibrates (95% CI) 4002 256 19.9 (17.6–22.6) 0.06
doi:10.1371/journal.pone.0002522.t007
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substantially outweigh any risk from statin prescribing. Graham
et al. showed incidence rates of hospitalized rhabdomyolysis to be
particularly elevated with combination of statin and fibrate
therapy, for example rhabdomyolysis incidence rates for ceriva-
satin (withdrawn in 2001) was 5.34 (95% 1.46–13.68) and for
cerivastatin and gemfibrozil this increased to 1035 (95% 389–
2117).[26] We were unable to calculate RR for rhabdomyolysis
using the case-crossover design as no events were recorded in the
exposed group. Using this UK primary care data, atorvastatin and
simvastatin reflect their place as the most commonly prescribed
statins and carry similar risk ratios for myopathy for 26 week
exposure: 15.2 and 19.5 respectively. Although the largest risks of
myopathy were for fluvastatin (RR 33.3 95% CI 16.8–66.0), this is
not a widely prescribed statin. The differences between cerivas-
tatin and atorvastatin RR for myopathy were found to be
statistically significant at 12 weeks RR 2.05 (95% CI 1.2–3.5)
which may reflect a more severe form of myopathy associated with
cerivastatin (withdrawn in 2001), than for example atorvastatin or
simvastatin. Similarly there were significant differences in RR for
myopathy for rosuvastatin and fluvastatin at 12 weeks and 26
weeks RR 3.0 (95% CI 1.6–5.7) and RR 3.4 (95% CI 1.2–8.8),
respectively. At 12 weeks, further differences in RR were identified
for atorvastatin vs. fluvastatin and pravastatin RR 0.39 (95% CI
0.24–0.63) and 0.53 (95% CI 0.40–0.70); and for simvastatin
versus fluvastatin and pravastatin RR 0.44 (95% CI 0.27–0.72)
and 0.61 (95% CI 0.46–0.79) respectively; however with longer
follow up and larger event numbers these differences may not be
significant. Analyses of fibrates prescribed alone showed an overall
risk for myalgia/myopathy with all fibrate class (without statin co-
prescriptions) was 12.8 (95% CI 6.3–25.9), however this was based
on much smaller numbers, and the CI were overlapping for
fibrates that had ever been prescribed following statin therapy.
A study in a US managed care group showed the RR of myositis
associated with statin monotherapy to be 2.8 (95% CI 1.3–5.9),
and combined with fibrate 9.1 (95% CI 3.5–23); however this is
unlikely to be representative of the general population.[6] A
similar previous study of myopathy using GPRD primary care
data showed results of a similar magnitude with ours, comparing
patients prescribed statins or fibrates with hyperlipidaemic and
normal controls. Although large relative risks for myopathy were
found for simvastatin RR 6.1 (95% CI 0.7–56.2) and bezafibrate
RR 39.0 (95% CI 9.1–170.0); the precision was lower as the
number of cases on which the estimate was based was very small
(1–5), and the time period of follow up was shorter: 1991–97.[7]
Using a 26 week exposure cut-off, the number of exposed events
4002 in 350 years in 16, 591 patients suggests an annual incidence
of around 11.4 for 16, 591 patients or 689 per million per year,
using THIN data, which is much higher than the annual incidence
of myopathy[7] or rhabdomyolysis previously estimated with statin
monotherapy;[26,27] however this may be partly due to the fact
we have included milder forms of myopathy and myalgia.
Although this study has a number of strengths, there are some
possible limitations. THIN and MediPlus provide data on a
population of 3 million active (and .5 million historic) patients
who are registered with a general practitioner, some with over 20
years of follow up. Comparison of THIN patient-demographic
statistics with census data indicates that patients included are
representative of the general population. People who are not
Table 8. Case-crossover comparison of myopathy/myalgia based on 16,591 users extracted from the THIN database (1991–2006):
Event rates using 52 week cut off for exposure.
Class of Drug Exposed Events Un-exposed Events Rate Ratio 52 weeks Standard error of RR
419 p-years 377 p-yrs
Atorvastatin 1448 36 21.6 (15.5–30.0) 0.17
Cerivastatin 62 4 29.5 (10.7–80.9) 0.52
Fluvastatin 93 8 35.6 (17.3–73.4) 0.37
Pravastatin 371 20 29.9 (19.1–46.9) 0.23
Rosuvastatin 135 2 14.9 (3.7–60.2) 0.71
Simvastatin 1864 59 24.5 (18.9–31.8) 0.13
All statins 3973 129 24.9 (20.9–29.7) 0.09
Ever use of statin with the following fibrate
Bezafibrate 85 11 26.6 (14.2–49.9) 0.32
Fenofibrate all 40 1 9.8 (1.3–71.2) 1.01
Ciprofibrate 16 3 37.7 (11.0–129.3) 0.63
All fibrates 141 15 29.0 (17.0–49.4) 0.27
ALL statins & fibrates (95% CI) 4114 144 25.7 (21.8–30.3) 0.08
doi:10.1371/journal.pone.0002522.t008
Figure 2. Case-crossover comparison of myopathy/myalgia
based on 16,591 users extracted from the THIN database
(1991–2006) for all statin and fibrate classes cumulative data
of rate ratio (95% CI) by year using 12 week cut off for
exposure.
doi:10.1371/journal.pone.0002522.g002
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this study; however this is a small percentage of the overall study
population.
Although statins can now be purchased from a pharmacy
without a prescription ‘‘over-the counter ’’ in the UK, this is
considerably more expensive than by prescription, accounts for
less than 1% of statin sales and is unlikely to have a large effect on
the results. To eliminate repeated codes for the same event we
analysed re-challenge data as having 6 months without any
preceding myopathy code and a statin prescription within the
preceding 2 weeks; although it is possible this may be biased if the
patient did not report symptoms to the GP in the interim period.
Confounders and Bias
Other conditions such as rare rheumatic diseases were excluded;
however due to the insidious nature of these diseases, these could
have been missed if symptoms were sub-clinical. Hence, it is
plausible that some cases of myopathy may have been due to
undiagnosed rheumatic disease, although we would not expect this
to inflate the RR associated with statin induced myopathy greatly.
One key advantage of the case-crossover design is that it
considerably reduces confounding as each case acts as its own
control. Conventional confounders such as age, sex, BMI, and
additional existing co morbidities such as renal and liver diseases
can therefore be accounted for. However, if these change over
time, it may be appropriate to calculate a ‘propensity score’ for the
individual which can included in the analyses (for example,
diagnoses which may lead to initiation of statin therapy) and to test
for confounding by exposure to other drugs. The case-crossover
approach is particularly suitable for detecting acute conditions,
such as ADRs of relatively acute onset. For case-crossover
comparisons the main confounder is any secular trend in
prescribing which will give rise to confounding by age.
Analysis examining RR of statin associated myopathy, stratify-
ing by calendar time periods showed possible secular trend of
decreasing RR. The adjusted RR (20.5) was similar to the crude
estimate of RR; however the fall in RR from 28.7 to 18.8 may be
explained by less use of concurrent fibrates with statins. The
difference in RR from 1995–98 compared with 2003–5 (12 week
data) was found to be statistically significant RR 1.79 (95% CI
1.2–2.8), and was similar for longer periods of exposure (26 weeks)
RR 1.53 (95% CI 1.2–2.9).
Where there are large RR associated with drug exposures; any
contamination of unexposed with exposed groups will affect the
estimates. This misclassification of exposure will mean that many
cases classified as ‘‘unexposed’’ are in reality ‘‘exposed’’. So in
effect we expect the true estimate for the RR of statin associated
myopathy will be higher than 19.9.
These and other techniques could be used to develop and apply
methods for exploiting primary care databases to infer causal
relationships between classes of drugs and classes of adverse events.
In the longer term, the development of computerised integrated
health records could allow the methods to applied to a much wider
population and thus greatly improve the detection rates of ADRs.
Because of the computerisation of general practice, the UK is well
placed to develop these new methods and compare them with
existing methods, although other European countries are also
adapting to computerised medical records. This would lead to the
development and testing of new methods of detecting adverse drug
reactions, which if successfully introduced, would have great
public health, clinical and economic benefits.
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